CTLA4 and cancer: Immune checkpoint inhibitors (ICIs) are generated antibodies that bind selectively and block the checkpoint proteins PD-1, PD-L1, and CTLA-4 expressed by tumor cells to escape the T cell-mediated antitumor response, therefore allowing T cells to recognize and eliminate cancer cells [20].